Affiliation:
1. Air Force Medical University (the Fourth Military Medical University)
2. Tangdu Hospital, Air Force Medical University (the Fourth Military Medical University)
3. Shaanxi University of Chinese Medicine
4. Air Force Medical Center of PLA
Abstract
Abstract
Background
Multiple sclerosis (MS) has been considered to be a T cell-dependent autoimmune disease of the central nervous system (CNS), and so does the experimental autoimmune encephalomyelitis (EAE) model. Recent studies have revealed a specific subset of CD8 T cells, known as CD8 follicular T cells (CD8+CXCR5+ T), are involved in antiviral, anti-tumor immunity, and systemic autoimmunity. While the role of CD8+CXCR5+ T cells in MS and EAE remains unclear.
Methods
We detected CD8+CXCR5+ T cell frequency in the peripheral blood of relapsing-remitting MS patients and healthy controls by flow cytometry and analyzed its correlation with disease activity. To show the dynamic changes and locations of CD8+CXCR5+ T cells in secondary lymphoid organs and CNS from EAE mice, flow cytometry and multiplexed immunohistochemistry were performed. RNA-seq, co-culture experiments and in vivo adoptive transfer were then conducted to reveal the phenotypes and functions of CD8+CXCR5+ T cells.
Results
Expansion of CD8+CXCR5+ T cells in MS patients and EAE mice was detected during the acute phase. In relapsing MS patients, elevated frequencies of circulating CD8+CXCR5+ T cells were positively correlated with new gadolinium-enhancement lesions of CNS. In EAE mice, CD8+CXCR5+ T cells infiltrated in ectopic lymphoid structures of spinal cords and germinal centers of spleens were positively correlated with clinical score and highly expressed ICOS, CD40L, IL-21 and IL-6. In vitro co-culture experiments and CD8+CXCR5+ T-adoptive mice both confirmed the ability of CD8+CXCR5+ T cells to provide B cell help and contribute to disease progression.
Conclusions
CD8+CXCR5+ T cells which bridged cytotoxic T cells and B cells in MS might be a promising target for developing disease-modifying treatments in the future.
Publisher
Research Square Platform LLC